anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicinal biotechnology, genetic engineering, virology. SUBSTANCE: invention relates to preparing the recombinant plasmid DNA pDES 20 encoding synthesis of hepatitis B virus surface antigen (HBsAg/ayw), the yeast strain Saccharomyces cerevisiae DAN-041/pDES 20 producing HBsAg/ayw and vaccine based on thereof. Constructed recombinant plasmid DNA pDES 20 has gene HBsAg/ayw under control of the modified promoter region of the yeast gene PH05 that is able to independent replication in E. coli and S. cerevisiae cells. Strain S. cerevisiae DAN-041/pDES 20 is obtained at yeast cells transformation with recombinant plasmid pDES 20. Strain produces antigen HBsAg/ayw at expression level up to 5 mg/1 l culture and showing 100% stability of plasmid under nonselective growth conditions. Vaccine for hepatitis B control contains an effective amount of hepatitis B virus recombinant surface antigen (HBsAg/ayw), adjuvant, preserving agent, physiologically acceptable dilutant and shows high immunogenicity at minimal by-side reactive effect. EFFECT: recombinant plasmid DNA indicated above, high expression level of antigen. 3 cl
PURPOSE: To provide a prosthesis which can be easily implanted and withstands high load for a long life by surrounding the respective holes with a valve formed on the surface of a shaft. CONSTITUTION: This prosthesis has a shaft 3 provided with many fine pocket holes 1 on the surface, and it can be implanted without cement. Each of the holes 1 is surrounded with a valve formed on the shaft surface. The hole 1 has a diameter of 25-100μm and a depth of 50-200μm. 20-100 holes 1 are formed per 1mm of the shaft surface. At least some of the holes 1 are oriented to form an acute angle to the direction of force applied to the bone by the prosthesis under the condition that the axial direction directed to the bottom is normal.
Dyspnea and chest pain represent 1.5% of general practice consultations. They may be a sign of many diseases, potentially serious. The concept of Gut Feelings brings a sense of alarm and reinsurance. The sense of alarm reflects a sense of mistrust about the patient's clinical situation, in the absence of objective argument. The sense of reinsurance reflects a sense of confidence about the patient's situation, in the absence of objective argument. Gut Feelings plays a key role in the diagnostic reasoning in general practice. A questionnaire measuring the Gut Feelings was validated in French after a linguistic validation procedure.

The objective of the research is to calculate the precision of the sense of alarm the general practitioner facing a consultant for chest pain or dyspnea and patient
###  Sedation: The most common adverse reaction to DEMSER is moderate to severe sedation, which has been observed in almost all patients. It occurs at both low and high dosages. Sedative effects begin within the first 24 hours of therapy, are maximal after two to three days, and tend to wane during the next few days. 

### Sedation usually is not obvious after one week unless the dosage is increased, but at dosages greater than 2000 mg/day some degree of sedation or fatigue may persist.

In most patients who experience sedation, temporary changes in sleep pattern occur following withdrawal of the drug. Changes consist of insomnia that may last for two or three days and feelings of increased alertness and ambition. Even patients who do not experience sedation while on DEMSER may report symptoms of psychic stimulation when the drug is discontinued.

###  Extrapyramidal Signs: Extrapyramidal signs such as drooling, speech difficulty, and tremor have been reported in approximately 10% of patients. These occasionally have been accompanied by trismus and frank parkinsonism.

###  Anxiety and Psychic Disturbances: Anxiety and psychic disturbances such as depression, hallucinations, disorientation, and confusion may occur. These effects seem to be dose-dependent and may disappear with reduction of dosage.
Diflunisal is rapidly and completely absorbed following oral administration with peak plasma concentrations occurring between 2 to 3 hours. The drug is excreted in the urine as two soluble glucuronide conjugates accounting for about 90% of the administered dose. Little or no diflunisal is excreted in the feces. Diflunisal appears in human milk in concentrations of 2% to 7% of those in plasma. More than 99% of diflunisal in plasma is bound to proteins.

As is the case with salicylic acid, concentration-dependent pharmacokinetics prevail when diflunisal is administered; a doubling of dosage produces a greater than doubling of drug accumulation. The effect becomes more apparent with repetitive doses. Following single doses, peak plasma concentrations of 41 ± 11 mcg/mL (mean ± S.D.) were observed following 250 mg doses, 87 ± 17 mcg/mL were observed following 500 mg and 124 ± 11 mcg/mL following single 1,000 mg doses. However, following administration of 250 mg b.i.d., a mean peak level of 56 ± 14 mcg/mL was observed on day 8, while the mean peak level after 500 mg b.i.d. for 11 days was 190 ± 33 mcg/mL. In contrast to salicylic acid which has a plasma half-life of 2 1/2 hours, the plasma half-life of diflunisal is 3 to 4 times longer (8 to 12 hours), because of a difluorophenyl substituent at carbon 1. Because of its long half-life and nonlinear pharmacokinetics, several days are required for diflunisal plasma levels to reach steady state following multiple doses. For this reason, an initial loading dose is necessary to shorten the time to reach steady-state levels, and 2 to 3 days of observation are necessary for evaluating changes in treatment regimens if a loading dose is not used.

Studies in baboons to determine passage across the blood-brain barrier have shown that only small quantities of diflunisal, under normal or acidotic conditions are transported into the cerebrospinal fluid (CSF). The ratio of blood/CSF concentrations after intravenous doses of 50 mg/kg or oral doses of 100 mg/kg of diflunisal was 100:1. In contrast, oral doses of 500 mg/kg of aspirin resulted in a blood/CSF ratio of 5:1.
The invention provides a drug used for reducing blood sugar which combines Chinese and western medicines and a preparation method thereof, relating to the field of the Chinese and western medicines. The invention is a drug used for reducing blood sugar which combines the Chinese and western medicines and a preparation method thereof and is developed by combining years of clinical experience with the modern clinical theory of traditional Chinese medicine. The invention includes suncured ginseng, white paeony root, medlar, glossy privet fruit, radix rehmanniae, dark plum fruit, seaweed, glibenclamide and phenformin. The invention is prepared by the steps of pretreatment of traditional Chinese medicinal materials, extract of traditional Chinese medicine ingredients, drying, sterilizing, crashing and storage, etc. The invention is light brown powder or granule with bitterish, tartish and saltish taste, and can be prepared into granule, tablet or capsule for oral administration. The invention has the functions of greatly invigorating primordial energy, nourishing yin, promoting body fluid production, tonifying the liver and the kidney, improving eyesight, relieving thirst, reducing blood sugar, regulating yin and yang and restoring the function of islet Beta cells, and the indication of the invention is II type diabetes mellitus. The invention takes traditional Chinese medicines asmain components and is added with minute quantity of western medicines to strengthen the function of reducing blood sugar and remarkable reduce the effect of the western medicine on the liver, the kidney and the stomach, thus improving curative effect, preventing complicating disease with low cost.
Our collaborator, Dr. Liping Zhao, developed a high fiber supplement (HFS), NBT-NM108. His recent study suggests an association between intake of NBT-NM108 and reduced gut dysbiosis and increased abundance of short chain fatty acid (SCFA)-producing gut bacteria. Since reports suggest that Relapsing Remitting Multiple Sclerosis (RRMS) may be associated with gut dysbiosis and decreased production of SCFAs, we will investigate the effect of NBT-NM108 on RRMS-associated gut dysbiosis. 50 RRMS patients will be enrolled. The first group (Group A) of RRMS patients (n=25) will receive NBT-NM108 for 12 weeks (High-fiber supplement group). The second group of RRMS patients (Group B) (n=25) will not consume any high fiber supplement. We will investigate the effect of NBT-NM108 on gut microbiota and immune parameters involved in MS.

We will also investigate the association between intestinal inflammation and relapse. The blood and fecal samples will be collected at the time of relapse and remission, and fecal Lipocalin 2 levels, an intestinal inflammation biomarker, will be examined.
Subjects with SCD that are older than 21 years old will receive standard of care for the first 12 months. They will then crossover to the comprehensive medication adherence management plan (Mobile DOT) after 1 month assessment period for the remaining 12 months.
Sarcoidosis is a multisystem, granulomatous disorder, most commonly affecting the lungs. Symptom burden is high, and quality of life (QoL) and social participation are negatively affected. In patients with pulmonary sarcoidosis, treatment is recommended in case of significant symptoms and/or impaired or deteriorating lung function. Evidence-based treatment recommendations are limited, outdated and largely based on expert opinion.

Prednisone is currently the first-choice therapy in pulmonary sarcoidosis and leads to short-term improvement of lung function. Unfortunately, prednisone has major side-effects and is associated with impaired QoL. Methotrexate is presently considered second-line therapy, and appears to have fewer side-effects. The investigators hypothesize that first-line treatment with methotrexate is as effective as prednisone, with fewer side-effects and better QoL.
OBJECTIVES: Hemangioma is a common soft tissue tumor that can be categorized mainly into cavernous, capillary, and venous subtypes. It usually develops in the head and neck and rarely in the external auditory canal (EAC).
METHODS: A systematic review of patients with capillary hemangioma of the EAC was performed. A computerized systematic search was conducted in PubMed, Scopus, and Web of Science to extract relevant studies for a qualitative review.
RESULTS: A total of 38 patients were included in the systematic review, and half of them were men. Hearing loss was the most common presenting feature (n = 19; 50%), followed by aural fullness (n = 15; 39.4%). Cavernous hemangioma was the predominant type (n = 22, 57.8%). Endaural and transcanal surgical approaches were the most frequent, with ten (26.3%) and nine (23.6%) cases, respectively. Most of the patients (n = 31; 81.5%) had no recurrence.
CONCLUSIONS: Hemangioma of the EAC may not be uncommon as healthcare professionals may expect. Hearing loss, aural fullness, and tinnitus are possible symptoms, but many patients remain asymptomatic. Surgical excision is the main effective management option, and complete resolution is the most prevalent outcome. Computed tomography assists in the diagnosis, but histopathological examination after resection is mandatory for the definitive diagnosis.
Patients are included at home after informed consent by the emergency medical team and transported during the following 2 hours to a cardiac intensive care unit were the treatment is purchased as well. Randomization process has been done previously with envelopes ; group A : pharmaceutical treatment alone , B pharmaceutical plus CPAP. Medical treatment includes furosemide and nitroglycerin (continuous perfusion and bolus), inotropes if needed, and all other specific treatment required (ex : anti antiarrhythmic drugs). Doses are free, adapted to the clinical response for respiratory and hemodynamic distress. CPAP is a passive high flow venturi system device alimented by a hyperbaric oxygen. FiO2 can be controlled and adapted to the pulsed oxygen saturation. PEP must be initially celled at least at 7.5 cmH2O and increased to 10 if well tolerated.
Daily CPI-0209 by mouth for days 1-28 of each 28-day cycle. Dose will be the maximum-tolerated dose found during the dose de-escalation cohort.
<P>PROBLEM TO BE SOLVED: To provide a composition for oral formulation which can mask unpleasant taste such as bitterness even though it contain a macrolide antibiotic and which has medicinal properties with high elution ability, and a process thereof.  <P>SOLUTION: In the composition for oral formulation in which a powdery composition comprising at least the macrolide antibiotic is coated with a polymer composition comprising a pH-independent and water-insoluble polymer and a polymer soluble in stomach, a ratio of the pH-independent and water-insoluble polymer to the polymer soluble in stomach (weight ratio) is adjusted to 1/1-1/20. The pH-independent and water-insoluble polymer may be, for example, a cellulose derivative (e.g. ethyl celluloses) and a (meth)acrylic polymer or the like. The macrolide antibiotic may be, for example, a 14-membered ring compound like clarithromycin.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The present invention relates to a tetramethylpyrazine compound emulsion and a preparation method and belongs to the field of medical technology. Prescription composition of the emulsion is counted by weight percentage comprising 0.05 percent to 5 percent of tetramethylpyrazine compound, 10 percent to 30 percent of triglyceride compound, 0.5 percent to 5 percent of emulsifier and 0 percent to 10 percent of addition agent and injection water or pharmaceutical water. The preparing process of the present invention of the tetramethylpyrazine compound emulsion comprises colostrum preparation, high pressure homogenization and moist heat sterilization and other steps. The emulsion is used for curing occlusive vascular disease, coronary heart disease, angina and other cardio-cerebrovascular disease. The present invention of the tetramethylpyrazine compound emulsion is capable of significantly enhancing drug efficacy and has the advantages of sustained release, targeting, and low toxicity. The present invention of the tetramethylpyrazine compound emulsion is good in stability, qualified in security test and accord with clinical medicine requirements. The present invention is used for intravenous and oral administration.
Background: Due to the limited role of chronic pain medication in military personnel and the distress caused to the military population, mindfulness-based therapy has been considered for the follow-up treatment of military personnel with chronic pain. The purpose of this review is to explore the effect and the implementation of mindfulness-based therapy for the military population with chronic pain. Methods: The keywords for the search included "mindfulness" AND ("pain" OR "chronic pain") AND ("military" OR "veteran"). The PubMed, Embase, and Cochrane Library databases were searched. The Cochrane Collaboration tool was used to independently assess the risk of bias of the included randomized controlled trials, and the Newcastle-Ottawa Scale was used to independently assess the risk of bias of the included case-control studies. Results: A total of 175 papers were identified; 65 duplicates were excluded, and 59 papers that did not meet the inclusion criteria were excluded after reading the titles and abstracts. The remaining 51 papers were read in full, 42 of which did not meet the inclusion criteria. Nine papers met the inclusion criteria and were included in the study. The nine studies included 507 veterans and 56 active-duty female military personnel. All pain interventions were mindfulness-based therapy, and all of them were integrated into or adapted from standard mindfulness courses. The results all showed that after mindfulness-based therapy, the relevant indicators improved. Conclusions: Mindfulness-based therapy is an effective treatment method for the military population with chronic pain. The review indicates that future research should focus on the best setting for mindfulness-based therapy, including the course content and time.
Russia's invasion of Ukraine has deeply impacted the nation's children, perhaps most strikingly those who remain in Ukraine and are confronted by the trauma of war. 2.5 million have fled their homes, but even those still at home endure explosions, violence, loss of loved ones, and an estimated average of 900 hours hiding in bunkers. Research in Ukraine shows high levels of child mental health (MH) problems, including anxiety, depression, interpersonal stress, and difficulty regulating emotions. PI Weisz works with child MH researchers and clinicians from Ukraine and 5 other countries (the GROW consortium) to plan psychological support for these children. The group has concluded that Ukrainian-language digital MH interventions teaching evidence-based coping skills are the optimum form of early psychological support at this time, given the massive number of war-exposed Ukrainian children, the dearth of professional clinicians, and the ready accessibility of digital devices. Brief digital interventions (BDIs) for MH have been found effective with children in \>90 randomized controlled trials (RCTs). They require no professional training or funding, and are easily implemented via digital devices used in nearly all schools. Ukrainian children may be helped via a BDI that teaches them evidence-based procedures for calming themselves when they experience distressing emotions.

The Harvard Lab for Youth Mental Health is collaborating with Ukrainian schools in the Zhytomyr region, which has been repeatedly targeted by Russian missiles since the first month of the invasion, spreading fear throughout the population and destroying airports, residential neighborhoods, hospitals, and at least one school. Children in Zhytomyr experience war-related MH problems identified in Ukrainian research reviews, including anxiety, sadness, and difficulty calming and regulating distressing negative emotions. Students will be offered a BDI that addresses these problems by teaching well-established skills that have robust empirical support: Project Calm teaches children to calm and regulate distressing emotions by using skills such as slowed breathing, relaxing of tense muscles, and peaceful mental imagery. This 30-minute BDI, which has been refined via student and school staff feedback over a 2-year period, is highly rated by children and teens, and has already been accessed \>1000 times in North America.

Project Calm will be tested via an RCT with a time-matched, school-related control activity; students will be randomized 50/50 to complete Project Calm after the baseline assessment or after a 2-month lag. Students in grades 4-12 will complete MH, wellbeing, and BDI-skills measures at baseline and 1-, 2-, 3-, and 4-months post-baseline. Data collection will span January - June of 2024. Findings may point the way to a highly scalable, accessible, and disseminable approach to MH support-easily implemented in schools or community settings-that could benefit Ukrainian children and, with translation and adaptation, war-affected children of other nations.
* Training on how to administer RUCONEST should be conducted by a qualified healthcare professional experienced in the treatment of HAE.
  * Appropriately trained patients may self-administer upon recognition of an HAE attack.
  * The recommended dose of RUCONEST is 50 U per kg with a maximum of 4200 U to be administered as a slow intravenous injection over approximately 5 minutes.



If the attack symptoms persist, an additional (second) dose can be administered at the recommended dose level. Do not exceed 4200 U per dose. No more than two doses should be administered within a 24-hour period.
Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. 

In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known.

The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells).
Idiopathic pulmonary fibrosis is a progressive lung disease characterized by excessive extracellular matrix accumulation and myofibroblast proliferation with limited treatment options available. M2 macrophages are pivotal in pulmonary fibrosis, where they induce the epithelial-to-mesenchymal and fibroblast-to-myofibroblast transitions. In this study, we evaluated whether MEL-dKLA, a hybrid peptide that can eliminate M2 macrophages, could attenuate pulmonary fibrosis in a cell co-culture system and in a bleomycin-induced mouse model. Our findings demonstrated that the removal of M2 macrophages using MEL-dKLA stimulated reprogramming to an antifibrotic environment, which effectively suppressed epithelial-to-mesenchymal and fibroblast-to-myofibroblast transition responses in lung epithelial and fibroblast cells and reduced extracellular matrix accumulation both in vivo and in vitro. Moreover, MEL-dKLA exhibited antifibrotic efficacy without damaging tissue-resident macrophages in the bleomycin-induced mouse model. Collectively, our findings suggest that MEL-dKLA may be a new therapeutic option for the treatment of idiopathic pulmonary fibrosis.
The goal of this study is to refine our proposed intervention (COMA-F) through an open pilot. The investigators will deliver an open pilot of the intervention (N=15 caregivers) to evaluate initial feasibility and acceptability using exit interviews and pre-post assessments.

The open pilot will take place at the Massachusetts General Hospital, University of North Carolina School of Medicine, and University of Maryland School of Medicine neurological intensive care units (NICUs) or step-down units using our established methodology successfully implemented during our previous R21 of our Recovering Together study. Study clinicians will deliver 6, 30 minute sessions of the intervention (at bedside or on Zoom, depending on participant preference). All participants will complete measures at baseline, and after completion of program (6 weeks). They will also complete measures of emotional distress weekly. At the completion of the program, participants will engage in a 5-10 minute exit interview where they will provide feedback of the intervention.
The treatment option for the modified XELOX group (study group) is 200 mg of sintilimab IV Drip Q3W, 600 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 78 mg/m2 IV Drip Q3W. After 6 cycles of treatment, patients could choose capecitabine + sintilimab maintenance with a maximum treatment duration of 2 years.